Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can sugar in urine predict kidney drug success?

NCT ID NCT07084038

Knowledge-focused Sponsor: Yuanjun Yang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 300 adults with chronic kidney disease who are already taking SGLT2 inhibitors. Researchers want to see if the amount of sugar in their urine is linked to changes in protein levels, a key marker of kidney damage. The goal is to find a simple way to tell if the drug is working well and possibly adjust doses for better results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SGLT2 inhibitor
What this could lead to
If successful, this could help doctors personalize SGLT2 inhibitor doses for better kidney protection in chronic kidney disease.
What could go wrong
This is an observational analysis, not a treatment trial. It may not lead to direct changes in care, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged ≥18 years diagnosed with chronic kidney disease (CKD) at the First Medical Center of the PLA General Hospital by March 2026, who regularly received oral administration of standard-dose SGLT2 inhibitors (SGLT2i), will be included. Medical records and laboratory test results (including routine blood tests and blood biochemical parameters) will be collected. Changes in 24-hour urinary glucose and urinary protein levels from baseline will be observed at 3 and 6 months after SGLT2i administration.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥18 years. Patients with a confirmed diagnosis of chronic kidney disease (CKD). Currently receiving stable, standard-dose SGLT2i therapy at screening. Proteinuria ≥0.15 g/24 h (or urine protein-to-creatinine ratio \[UPCR\] ≥440 mg/g or urine albumin-to-creatinine ratio \[UACR\] ≥300 mg/g) at screening. Estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73m² calculated by the CKD-EPI creatinine equation at screening. Willing and able to provide written informed consent. Exclusion Criteria: Discontinuation of SGLT2i during the follow-up period. History of symptomatic hypotension (systolic blood pressure\<90 mmHg) without antihypertensive medication, or current hypotensive episode at screening. Unstable renal function (e.g., acute kidney injury or rapidly progressive glomerulonephritis with a \>50% decline in eGFR within 3 months prior to screening). Use of corticosteroids or having an indication for corticosteroid therapy within the past 6 months. Receipt of immunosuppressive therapy or having an indication for immunosuppressive therapy within the past 6 months. History of intolerance to SGLT2 inhibitors. History of ketoacidosis within the past 5 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

Contacts and locations

Locations

  • Chinese PLA General Hospital,

    Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.